KPNB1-mediated nuclear import in cancer

Qiwen Shi; Mengxia Lin; Xiang Cheng; Ziyuan Zhang; Shufen Deng; Ke Lang; Zhikun Yang; Xuanrong Sun

doi:10.1016/j.ejphar.2023.175925

KPNB1-mediated nuclear import in cancer

Eur J Pharmacol. 2023 Sep 15:955:175925. doi: 10.1016/j.ejphar.2023.175925. Epub 2023 Jul 18.

Authors

Qiwen Shi¹, Mengxia Lin¹, Xiang Cheng¹, Ziyuan Zhang¹, Shufen Deng¹, Ke Lang¹, Zhikun Yang¹, Xuanrong Sun²

Affiliations

¹ Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China.
² Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China. Electronic address: sunxr@zjut.edu.cn.

PMID: 37473981
DOI: 10.1016/j.ejphar.2023.175925

Abstract

Dysregulation of nucleocytoplasmic shuttling impairs cellular homeostasis and promotes cancer development. KPNB1 is a member of karyopherin β family, mediating the transportation of proteins from the cytoplasm to the nucleus. In a variety of cancers, the expression of KPNB1 is upregulated to facilitate tumor growth and progression. Both downregulation of KPNB1 level and inhibition of KPNB1 activity prevent the entry of cancer-related transcription factors into the nucleus, subsequently suppressing the proliferation and metastasis of cancer cells. Currently, five KPNB1 inhibitors have been reported and exhibited good efficacy against cancer. This paper provides an overview of the role and mechanism of KPNB1 in different cancers and KPNB1-targeted anticancer compounds which hold promise for the future.

Keywords: Apoptosis; Cancer; Cell cycle; KPNB1; Nucleocytoplasmic transport.

Publication types

Review

MeSH terms

Active Transport, Cell Nucleus
Cell Nucleus / metabolism
Down-Regulation
Humans
Neoplasms* / drug therapy
Neoplasms* / metabolism
beta Karyopherins* / genetics
beta Karyopherins* / metabolism

Substances

beta Karyopherins
KPNB1 protein, human